NCT06436846|Recruiting
Genomic Risk in Retroperitoneal Sarcoma
Characterization of the Genomic Risk Underlying Retroperitoneal Liposarcoma
Loading search results
Characterization of the Genomic Risk Underlying Retroperitoneal Liposarcoma
Sponsor study identifier
observational
50
1 country
1
Study Start
March 7, 2022
Actual (reported)Primary Completion
June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
The protocol intends to explore the biology which may underlie recurrences of retroperitoneal liposarcoma. Surgery remains the only curative intent intervention for this disease. Often, tumors recur in locations within the retroperitoneum remote from the original primary tumor. This study hypothesizes that normal appearing retroperitoneal fat actually harbors underlying genetic changes which predispose to development of future liposarcoma. To accomplish this goal, retroperitoneal fat is sampled from quadrants within and remote from the primary tumor and is subsequently subjected to genetic analyses looking for such predisposing factors.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 7, 2022
Actual (reported)May 7, 2024
Actual (reported)May 31, 2024
Actual (reported)June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Presence of MDM2 amplification in "normal" retroperitoneal fat
MDM2 amplification of primary tumors and fat samples will be tested by immunohistochemistry and/or fluorescence in situ hybridization.
Through study completion, an average of 3 years
The entire study is a singular cohort of patients with retroperitoneal liposarcoma (index or recurrent) who undergo surgical resection of their tumor.
Patients in this observational study are undergoing planned surgical resection of their retroperitoneal sarcoma as prescribed by their primary surgeon and treatment team. In addition to removal of the primary tumor, surgeons remove 4 samples of retroperitoneal fat and a sample of subcutaneous fat for further study at the time of the operation.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adult patients (age 18 years or older) with retroperitoneal tumors suspicious for liposarcoma.
Fox Chase Cancer Center
Philadelphia, Pennsylvania, 19111, United States
Samples of retroperitoneal fat (x4), subcutaneous fat (x1), primary tumor samples (x3) - all collected during surgery for tumor.
First Submitted
May 7, 2024
First Posted
May 31, 2024
Study Start
March 7, 2022
Actual (reported)Primary Completion
June 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Exercise and Soft Tissue Sarcoma
Contact the study team to confirm eligibility.
Study Completion
August 1, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
May 31, 2024
Record last verified: 2024-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: